“This is exciting news for the medical community and patients in Japan,” said Catherine Burzik, KCI president and chief executive officer. “Our vision is to transform wound care in Japan by delivering advanced healing solutions and clinical know-how in a way that produces unparalleled outcomes.”
The company anticipates that in October the MHLW will review that all necessary regulatory steps have been addressed before the application is taken to the Minister’s Office for signature.
Following regulatory approval this fall, KCI anticipates reimbursement approval in the first half of 2010. Once reimbursement approval is obtained, KCI will begin commercializing V.A.C. Therapy in Japan.
KCI is a company developing advanced wound care, negative pressure wound therapy (NPWT) and therapeutic support systems.
